Organon & Co. (OGN) 주식 분석

회사 개요

Organon & Co. (OGN) is a healthcare enterprise focused on the development and distribution of prescription therapies and medical devices specifically for women's health solutions. The company operates within the Healthcare sector, more specifically classified under the industry of Drug Manufacturers - General, which implies a focus on pharmaceutical production and commercialization rather than biotechnology development or medical device manufacturing alone. The organization maintains a workforce of approximately 10,000 employees, indicating a substantial operational scale typical of established pharmaceutical entities. With a market capitalization of $1.52B and annual revenue of $6.22B, the company holds a significant position in the global market, though the relatively low market cap relative to its revenue suggests it may be undervalued or reflecting specific market conditions.

재무 건전성

The company reported total revenue of $6.22B over the trailing twelve months, generating a net income of $187.00M and an EBITDA of $1.65B. The substantial gap between the $6.22B in revenue and the $187.00M in net income reveals a cost structure where operating expenses and taxes consume roughly 97% of gross revenue before reaching the bottom line, a common characteristic in capital-intensive pharmaceutical sectors. Free cash flow stands at $190.12M, which provides the company with essential financial flexibility to fund research and development activities or manage capital expenditures without immediate reliance on external financing. Regarding profitability margins, the gross margin is 54.3%, reflecting the pricing power and manufacturing efficiency of the drug portfolio, while the operating margin sits at 16.2% and the profit margin at 3.0%, indicating that significant overhead costs, such as sales, marketing, and R&D, are deducted from gross profits. The balance sheet shows $574.00M in cash against $8.80B in debt, resulting in a debt-to-equity ratio of 1170.21, which characterizes the company as highly leveraged. Despite the high leverage, the current ratio of 1.82 indicates that the company holds sufficient current assets to cover its short-term liabilities, suggesting adequate short-term liquidity management. Furthermore, the return on equity is 30.6% and the return on assets is 6.2%, metrics that demonstrate how effectively management utilizes shareholder capital and total assets to generate returns, with the high ROE partly attributable to the leverage on the balance sheet.

밸류에이션 평가

The valuation metrics show a trailing P/E ratio of 8.11 and a forward P/E of 1.57, where the significant difference between these figures implies that the market expects earnings to grow substantially in the future relative to current levels. The price-to-book ratio is 2.02, suggesting that the stock is trading at a slight premium of roughly double its book value, which can indicate investor confidence in the brand's intangible assets or future growth potential. Alternative valuation measures include a price-to-sales ratio of 0.24 and an EV/EBITDA of 5.89, which collectively suggest that the company is valued very cheaply relative to its sales and earnings generation capabilities. The stock has a 52-week high of $15.85 and a 52-week low of $5.83; while the exact current price is not provided in the facts, the wide trading range indicates significant price volatility over the past year. The beta value is 0.57, which means the stock's price volatility is less than half that of the broader market, making it a relatively defensive holding compared to the overall market index.

Growth & Income

Revenue growth year-over-year is -5.3%, while earnings growth is marked as N/A in the available data, meaning it is impossible to determine if earnings are growing faster or slower than revenue based on the current fiscal year comparison alone. For dividend payers, the company offers a dividend yield of 1.4% with a payout ratio of 47.2%, which indicates a moderate payout level that is generally sustainable given the company's reported net income, though the negative revenue growth warrants monitoring of future earnings capacity. Since the earnings growth data is unavailable rather than explicitly zero, the specific claim regarding reinvestment into growth over dividends cannot be definitively stated for this period without assuming zero growth, but the payout ratio suggests a balance between shareholder returns and retention. The overall growth and income profile is characterized by a contraction in top-line revenue, a highly leveraged balance sheet, and a modest dividend yield that provides income to holders despite the lack of confirmed earnings expansion in the trailing year.